Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children

Vaccine

Volumn 14, Issue 3, 1996, Pages 207-211

  Raz, Raul ^a   Dagan, Ron ^a,b   Gallil, Aharon ^a   Brill, Gerta ^a   Kassis, Imad ^b   Koren, Ronit ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c Research Division   (Israel)

Author keywords

Children; Hepatitis B vaccine; Immunization; Mammalian cell; Pre S1; Pre S2; Recombinant

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; YCBIO HEP B;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION; VACCINATION;

CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; ISRAEL; MALE; PROTEIN PRECURSORS; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 0030023915     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00185-4     Document Type: Article

References (29)

1. West, D.J., Calandra, G.B. and Ellis, R.W. Vaccination of infants and children against hepatitis B. Ped. Clin. N. Am. 1990, 37, 585-601
2. Even-Chen, Z., Drummer, H., Levanon, A., Panet, A. and Gorecki, M. Development of a novel hepatitis B vaccine containing Pre-S1. In: Biologicals from Recombinant Microorganisms and Animal Cells (Eds White, M.D., Reuveny, S. and Shafferman, A.). VT, Weinheim, Germany, 1990, pp. 534-547
3. Heerman, K.H., Goldman, V., Schwartz, W., Seyffarth, T., Baumgarten, H. and Gerlich, W.H. Large surface proteins of hepatitis B virus containing the Pre-S sequences. J. Virol. 1984, 52, 3496-4002
4. Emini, E.A., Larson, V., Eichberg, J. et al. Protective effect of a synthetic peptide comprising the complete PreS2 region of the hepatitis B virus surface protein. J. Med. Virol. 1989, 28, 7-12
5. Milich, D.R., Thornton, G.B., Neurath, A.R., Kent, S.B., Michel, M.L. and Tiollai, J.P. Enhanced immunogenicity of the Pre-S region of hepatitis B surface antigen. Science 1985, 228, 1195-1199
6. Gerlich, W., Deepen, R., Heerman, K.H., Krone, R., Lu, X.Y., Seifer, M. and Thomssen, R. Protective prevention of hepatitis B virus antigens other than the S gene protein. Vaccine 1990, 8, 563-568
7. Shouval, D., Ilan, Y., Adler, R., Deepen, R. and Gerlich, W.H. Improved immunogenicity in mice of a recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in HBs particles (Abstract) J. Hepatol. 1991, 13, S71
8. Neurath, A.R., Kent, S.B.H., Strick, N., Taylor, P. and Stevens, C.E. Hepatitis B virus contains Pre-S gene-encoded domains. Nature 1985, 315, 154-156
9. Milich, D.R., McNamara, M.K., McLachlan, A., Thornton, G.B. and Chisari, F.U. Distinct H-2-linked regulation of T-cell dependent responses to the Pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of non-responsiveness to the S region. Proc. Natl Acad. Sci. USA 1985, 82, 8168-8172
10. Bucher, B., Francioli, P., Geudelin, B., Fritzell, B., Lavanchy, D. and Frei, P.C. Immunogenicity of a recombinant Pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster. Eur. J. Clin. Microbiol. Infect. Dis. 1994, 13, 212-217
11. Jungers, P., Chaveau, P., Couroucé, A.M. et al. Immunogenicity of the recombinant GenHeval B Pasteur vaccine against hepatitis B in chronic uremic patients. J. Infect. Dis. 1994, 169, 399-402
12. Yap, I., Guan, R., Chan, S.H. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein - a preliminary study on immunogenicity. Vaccine 1992, 10, 439-442
13. Shouval, D., Ilan, Y., Hourvitz, A. et al. Immunogenicity of a mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S2 and Pre-S1 antigens: a preliminary report. In: Viral Hepatitis and Liver Disease (8th Triennial Congress) (Eds Nishioka, K., Suzuki, H., Mishiro, S. and Oda, T.). Springer, Tokyo. 1994
14. Madalinski, K., Zychowicz, C., Gornicki, J. et al. Immunogenicity in children of recombinant hepatitis vaccine containing S, Pre-S2 and Pre-S1 antigens II. Persistence of antibodies. Polish J. Immunol. 1994, 19, 333-340
15. Dreesman, G.R., Hollinger, F.B. and Melnick, J.L. Biophysical and biochemical properties of purified preparations of hepatitis B surface antigen (HBsAg). Am. J. Med. Sci. 1975, 270, 123-129
16. International Application published under the Patent Cooperation Treaty, publication no. WO 90/10058, 7 September 1990
17. Hollinger, F.B. et al. Response to hepatitis B vaccine in a young adult population. In: Viral Hepatitis (Eds Szmuness, W. et al.). Franklin Inst. Press, Philadelphia, 1982, pp. 451-466
18. Jilg, W., Schmidt, M., Deinhardt, F. and Zachoval, R. Hepatitis B vaccination: how long does protection last? Lancet 1984, ii, 458
19. Andre, F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am. J. Med. 1989, 87 (Suppl. 3A), 14S-20S
20. Shouval, D., Ilan, Y., Adler, R. et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 1994, 12, 1453-1454
21. Manyike, P.T., Aspinall, S. and Summers, R.S. Immunogenicity of recombinant hepatitis B vaccine in urban black children from Ga-Rankuwa, Bophuthatswana, South Africa. Ped. Infect. Dis. J. 1992, 11, 726-730
22. Goh, K.T., Tan, K.L., Kong, K.H., Oon, C.J. and Chan, S.H. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four year follow-up study. WHO Bull. OMS 1992, 70, 233-239
23. West, D.J., Calandra, G.B. and Ellis, R.W. Vaccination of infants and children against hepatitis B. Ped. Clin. N. Am. 1990, 37, 585-601
24. Andre, F.E. and Safary, A. Summary of clinical findings on Engerix-B, or genetically engineered yeast-derived hepatitis B vaccine. Postgrad. Med. J. 1987, 63 (Suppl. 2), 169-178
25. Andre, F.E. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990, 8 (Suppl.), S74-S78
26. Michel, M.L., Pontisso, P., Sobczak, E., Malpiece, Y., Streeck, R.E. and Tiollais, P. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. Proc. Natl Acad. Sci. USA 1984, 81, 7708-7712
27. Persing, D.H., Varmus, H.E. and Ganem, D. A frameshift mutation in the Pre-S region of the human hepatitis B virus genome allows production of surface antigen particles but eliminates binding to polymerized albumin. Proc. Natl Acad. Sci. USA 1985, 82, 3440-3444
28. Milich, D.R. Immunological response to Pre-S antigens of the hepatitis B virus. Viral Immun. 1987, 1, 83-96
29. Neurath, A.R., Kent, S.B.H., Serick, N. and Parker, K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986, 46, 429-436